Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

This study is ongoing, but not recruiting participants.

Study NCT00441090 Information provided by Eisai Inc.

First Received: February 27, 2007 Last Updated: August 27, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

Placebo
AKR-501 Tablets

Sponsors listed in this trial

Eisai Inc.